Cystic fibrosis is a genetic disorder affecting the entire body and associated with respiratory exacerbations, impaired quality of life and reduced life expectancy. The therapeutic management of cystic fibrosis has been profoundly changed by the recent arrival of a combination of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators, Elexacaftor-Tezacaftor-Ivacaftor (ETI), which improve quality of life, respiratory function and reducing the number of exacerbations. The impact of these treatments on exercise adaptation has not been clearly identified.
The main objective is to estimate the prevalence of ventilatory reserve amputation during submaximal exercise testing assessed by the 6-minute walk test (6MWT) in patients with cystic fibrosis treated with ETIs.
Male or female
Adult aged 18 or over
Suffering from cystic fibrosis
Treated at the CRCM in Lille and Créteil
Medical contraindication or inability to perform a stress test according to ERS recommendations
Absolute contraindications
Exacerbation of the condition in the 4 weeks preceding the V1 visit (27).
Pregnant or breastfeeding women
University Hospital, Lille
Lead sponsor
Vaincre la Mucoviscidose
Collaborator